Comparison of New Glucose-Lowering Drugs on the Risk of Pancreatitis in Type 2 Diabetes: A Network Meta-Analysis

医学 胰腺炎 内科学 2型糖尿病 糖尿病 荟萃分析 急性胰腺炎 重症监护医学 内分泌学
作者
Xuexue Zhang,Miaoran Wang,Xujie Wang,Zhengchuan Zhu,Wantong Zhang,Zhongyang Zhou,Wei Tang,Qiuyan Li
出处
期刊:Endocrine Practice [Elsevier BV]
卷期号:28 (3): 333-341 被引量:17
标识
DOI:10.1016/j.eprac.2021.12.007
摘要

Abstract

Objective

To explore whether new glucose-lowering drugs increase the risk of pancreatitis in individuals with type 2 diabetes. This present network meta-analysis aimed to investigate the risk of pancreatitis associated with the use of glucagon-like peptide-1 (GLP-1) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors in the treatment of type 2 diabetes mellitus.

Methods

PubMed, Web of Science, Embase, and the Cochrane Library were searched. The literature was published from the date of their inception to July 21, 2021, including placebo-controlled or head-to-head trials of 2 new glucose-lowering drugs. The relative ratio (RR) and 95% confidence interval (CI) were used to assess the risk of GLP-1 agonists and DPP-4 inhibitors for pancreatitis or pancreatic cancer among patients with type 2 diabetes.

Results

Seventeen studies were identified, covered 102 257 participants. The pooled results showed a neutral relationship between GLP-1 agonists and pancreatitis (overall RR, 0.96; 95% CI, 0.31-3.00) or pancreatic cancer (overall RR, 1.10; 95% CI, 0.31-4.10) compared with placebo. Meanwhile, DPP-4 inhibitors were not associated with the increased risk of pancreatitis (overall RR, 1.60; 95% CI, 0.25-11.00) or pancreatic cancer (overall RR, 0.79; 95% CI, 0.26-2.40). Among them, lixisenatide and saxagliptin may be the safest drugs compared with other drugs according to the ranking of probability. Sensitivity and subgroup analysis confirmed the stability of the core results.

Conclusion

The most obvious finding of this study is that GLP-1 agonists and DPP-4 inhibitors are safe with respect to the risk of pancreatitis and pancreatic cancer compared with placebo. This conclusion may provide useful evidence for correlated clinical researches.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
虚心醉蝶完成签到 ,获得积分10
刚刚
ZhiyunXu2012完成签到 ,获得积分10
1秒前
FashionBoy应助科研通管家采纳,获得10
2秒前
桐桐应助科研通管家采纳,获得10
3秒前
许鸽应助科研通管家采纳,获得30
3秒前
搜集达人应助科研通管家采纳,获得10
3秒前
赘婿应助科研通管家采纳,获得10
3秒前
感动满天完成签到,获得积分10
3秒前
Nick完成签到 ,获得积分0
5秒前
6秒前
7秒前
小事完成签到 ,获得积分10
8秒前
听闻韬声依旧完成签到 ,获得积分10
12秒前
沐沐心完成签到 ,获得积分10
14秒前
HHW完成签到,获得积分10
22秒前
sdbz001完成签到,获得积分0
23秒前
27秒前
29秒前
王士钰完成签到,获得积分10
30秒前
慕容飞凤完成签到,获得积分10
31秒前
张大侠发布了新的文献求助10
32秒前
xbb88发布了新的文献求助10
33秒前
慎之完成签到 ,获得积分10
34秒前
语恒完成签到,获得积分10
34秒前
莫林在发布了新的文献求助60
34秒前
alixy完成签到,获得积分10
35秒前
golfgold完成签到,获得积分10
36秒前
桐桐应助与枫采纳,获得10
36秒前
h w wang完成签到,获得积分10
38秒前
叶问夏完成签到 ,获得积分10
38秒前
目土土完成签到 ,获得积分10
40秒前
无尘完成签到 ,获得积分10
43秒前
体贴的叛逆者完成签到,获得积分10
43秒前
17852573662完成签到,获得积分10
43秒前
44秒前
三号技师完成签到,获得积分10
45秒前
46秒前
与枫发布了新的文献求助10
49秒前
脸小呆呆完成签到 ,获得积分10
51秒前
michaelxia发布了新的文献求助10
51秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968559
求助须知:如何正确求助?哪些是违规求助? 3513391
关于积分的说明 11167370
捐赠科研通 3248808
什么是DOI,文献DOI怎么找? 1794465
邀请新用户注册赠送积分活动 875116
科研通“疑难数据库(出版商)”最低求助积分说明 804664